Navigation Links
Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
Date:5/12/2008

Results show promising neurological recovery in severely-injured, acute

cervical spinal cord injury patients treated with Cethrin

HOPKINTON, Mass., May 12 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its potential to restore motor and sensory function after spinal cord injury, or SCI. The trial enrolled a total of 48 patients of which 37 have reached the final 12 month follow up evaluation. The data for these first 37 patients indicate that at 6 and 12 months after treatment, 38% (5 of 13) of cervical injury patients showed marked recovery of motor and sensory function after treatment as measured by a 2-grade or better improvement in the American Spinal Injury Association, or ASIA, Impairment Scale. Analysis of the data by dose group indicates that Cethrin doses of 1 and 3 mg appear to be the most beneficial for cervical patients with 43% (3 of 7) showing the same 2-grade or better recovery of motor and sensory function.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

"The safety and efficacy observations of the Cethrin trial continue to be encouraging. Many patients have shown a degree of improvement far above the expected outcome," commented Dr. Mark Hurtt, Alseres' Chief Medical Officer. "The interim results of the Phase I/IIa study have helped identify what we believe will be the most effective dose range to carry into our Phase IIb trial later this year."

Based on these results, Alseres intends to move forward with its previ
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
2. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
3. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
4. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
7. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
10. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
11. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... Mass. , Aug. 30, 2014  Boston ... its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) ... clinical trial investigating vagus nerve stimulation (VNS) for ... M.D., Ph.D., Professor of Therapeutics and Cardiology and ... Institut National de la Sante et de la ...
(Date:8/30/2014)... Aug. 30, 2014   Royal Philips  (NYSE: PHG, ... a new ultrasound system designed to enable global ... increasing patient volumes and cost pressures. Making its debut ... in Barcelona this week, Affiniti ... patients with fewer resources deliver high quality patient care. ...
(Date:8/29/2014)... DALLAS , Aug. 29, 2014 /PRNewswire-iReach/ -- ... Crystallography Scanner Industry, 2009-2019 is a professional and ... X-Ray Crystallography Scanner industry . The report firstly ... including its classification, application and manufacturing technology. The ... of X-Ray Crystallography Scanner listing their product specification, ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... ANNAPOLIS, Md., Oct. 13, 2011 PharmAthene, Inc. (NYSE Amex: ... its legal brief in response to SIGA Technologies, motion for ... Court of Chancery had issued a ruling in its litigation ... over 10 years from all sales of ST-246 and related ...
... 13, 2011 A Medco Health Solutions, Inc. (NYSE: ... 38 percent of patients prescribed Plavix® (clopidogrel)—an anti-platelet drug ... also using another drug that would impede its effectiveness. ... analysis also showed that primary care physicians seem willing ...
Cached Medicine Technology:PharmAthene Submits Legal Brief in Response to SIGA Technologies' Motion for Reargument 2PharmAthene Submits Legal Brief in Response to SIGA Technologies' Motion for Reargument 3Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 2Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 3Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 4
(Date:8/30/2014)... Albany, New York (PRWEB) August 30, 2014 ... a combination of Nutrition and Pharameuticals. Nutraceuticals is ... by extracting healthy ingredients from natural food sources. ... specific health benefits to the human body. Nutraceutical ... multivitamins, diet supplements, fortified foods and more. Although ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 RB SEO ... cost SEO service for small businesses. , RBSEO Services ... cannot afford costly search engine optimization service. So, the ... small businesses into account. , On being asked ... have introduced this low cost SEO service because many ...
(Date:8/30/2014)... 2014 Ticket Down is ... Championship tickets in NYC. This popular ticket ... for all day session, evening session, courtside seats, grandstand ... this prestigious Grand Slam Tournament. , The 2014 U.S. ... US Open Tennis Championship: Men's/Women's 3rd Round - Session ...
(Date:8/30/2014)... The establishment and creation of Ideal ... of the main strategies of the Church of ... around the world. , Architecturally stellar buildings with ... and trainers deliver L. Ron Hubbard's spiritual technology ... demonstrate that significant reduction in crime, major decrease ...
(Date:8/30/2014)... Tenn. (PRWEB) August 30, 2014 ... around the country for the past several years, ... Tennessee Hyperbaric Center have announced a scholarship program ... This announcement follows a meeting held this summer ... In recent years, reporters have shed light on ...
Breaking Medicine News(10 mins):Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2
... all will have fatal consequences. But because clinicians find it ... do not receive the therapy fits their disease. , ... that each course of treatment is as individual as the ... on a combination of MRI and ultrasound is able ...
... to health care suffers when they spend any timeeven a ... appearing in the February 2009 issue of Medical Care ... for as few as four months, there is a 2.8 ... care visit, according to the study, Partial-Year Insurance Coverage and ...
... BIRMINGHAM, Ala., Jan. 26 The National Center for ... the death of 15-year-old,Kentucky high school football player Max ... High School coach David Stinson on,Thursday. , ... teammates, and coaches of this young,man," said Dr. Larry ...
... by members -- and challenge Washington, D.C. officials to ... Jan. 26 On Friday, SEIU officials in Washington, ... the undemocratic transfer of 65,000 nursing home and homecare ... an immediate takeover and the expulsion of more than ...
... about possible link to heart disease to rest , , MONDAY, ... omega-6 fatty acids found in vegetable oils, nuts and seeds ... science advisory from the American Heart Association claims. , "There ... that omega-6 fatty acids might be bad," said William S. ...
... Ga., Jan. 26 Aflac Incorporated (NYSE:, AFL ... financial results,after the market closes on February 2, 2009. ... earnings release, Aflac Incorporated will webcast,an analyst meeting on ... Chairman and CEO Daniel P. Amos will discuss Aflac,s ...
Cached Medicine News:Health News:An individualized approach to breast cancer treatment 2Health News:New study: Short coverage lapses limit children's access to health care services 2Health News:National Center for Sports Safety Responds to Indictment of Kentucky Coach 2Health News:Healthcare Workers Answer SEIU Ultimatum 2Health News:Omega-6 Fatty Acids Can Be Good for You 2Health News:Omega-6 Fatty Acids Can Be Good for You 3Health News:Aflac Incorporated To Release Fourth Quarter Results on February 2, 2009 2
Nucleus Hydrodissection Cannula, 25 g. Angled with flattened tip. 7 mm angled shaft with flattened tip for insertion under the capsular flap. Overall length 19 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with right hook. 10 mm angled shaft with 2.5 mm right hook tip. Overall length 20 mm. 5/box....
Retinal Hydrodissection Cannula. 20 gauge shaft tapers to 41 gauge I.D. flexible tip. Packaged sterile. 5/Box....
Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g. Overall length 16 mm. 5/box....
Medicine Products: